Drug Combination Details
| General Information of the Combination (ID: C85986) | |||||
|---|---|---|---|---|---|
| Name | Genistein NP Info | + | 17-beta estradiol Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] | ||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | DNMT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | ESR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
GE can epigenetically increase ERalpha expression by inhibition of DNMT1 expression which in turn increases apoptotic effect of E2. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | COMT | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CYP1A1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Genistein decreases the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. | |||||
